At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative, multi-modal pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. Our approach is scientifically and clinically cutting edge and is both targeted and locally acting at the site of inflammation.
ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and will be undertaking a Phase 2 study in moderate ulcerative colitis (UC) this year. ADS051 is nearly completing enrollment in a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor (NLRP3 & NLRP1) in discovery phase which is being initially explored in respiratory inflammation, and dermal application with multiple future therapeutic areas to pursue.